Arcellx's Acquisition by Gilead Sciences and Its Impact on Stock Performance

Core Insights - Gilead Sciences intends to acquire Arcellx for up to $7.8 billion, marking its largest deal since 2020, aimed at enhancing its cancer treatment portfolio [2][5] - The acquisition has led to a significant increase in Arcellx's stock price, which rose 77.8% in premarket trading, reflecting a 77.50% increase to $113.80 [2][3][5] - Arcellx's market capitalization is approximately $6.58 billion, with a trading volume of 27.91 million shares, indicating strong investor confidence following the acquisition announcement [4] Stock Performance - At the time of the acquisition announcement, Arcellx's stock was trading at $113.81, with a price target set at $115 by Cory Kasimov from Evercore ISI, indicating a slight 1.04% difference [1][5] - The stock has fluctuated between $113.72 and $114.26, marking its highest price in the past year, while the lowest price for the year was $47.86 [3]